What factors should be considered when selecting treatment for an elderly AML patient?

During the 63rd ASH Annual Meeting and Exposition, the AML Hub was pleased to speak with Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked, What factors should be considered when selecting treatment for an elderly AML patient?

Platzbecker begins by highlighting that the term 'elderly patients' can be a moving target when considering treatment choices. He discusses hypomethylating agents (HMAs) as the primary therapy for this group, and other treatment regimens and their appropriate settings. He notes that patients over 75, especially those with comorbidities and frailty concerns, are rarely considered for allogeneic transplant or intensive therapy. Platzbecker hopes to see further clinical trials, but for now, encourages clinicians to stick to the inclusion/exclusion criteria of the VIALE-A trial while still considering novel developments and clinical trials.